Aldeyra Therapeutics, Inc. announced that the Company has formally requested that the Division of Ophthalmology of the U.S. Food and Drug Administration…
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a review jurisdiction
- Product
- ADX-2191
- Indication
- primary vitreoretinal lymphoma
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The withdrawal of the SPA and request to change FDA review division introduce uncertainty, likely extending development timelines and increasing cash burn, which could depress the stock.
Market read
The filing signals a potential delay in a rare‑disease drug program, which could trigger a sell‑off in ALDX and influence sentiment toward similar biotech pipelines.
What to watch
Potential for the company to pivot ADX‑2191 to other indications or to focus on its reproxalap program.
Background
Aldeyra is a clinical‑stage biotech developing ADX‑2191 for primary vitreoretinal lymphoma, a rare eye cancer. The company previously received a Complete Response Letter and had a Special Protocol Assessment in place.
Ticker impact
Aldeyra Therapeutics filed an 8‑K reporting it requested the FDA to transfer its IND for ADX‑2191 to a different review division and withdrew its Special Protocol Assessment, creating regulatory uncertainty.
downward pressure as investors price in potential delays and higher cash‑burn.
The filing is a primary disclosure of a material regulatory setback for a late‑stage drug candidate, which historically triggers sell‑offs in biotech stocks.
Market effects
May weigh on other ophthalmology and lymphoma biotech peers as regulatory delays raise risk perception.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking rare‑disease drug pipelines.
Counterpoint
If the FDA approves the transfer, the IND could benefit from hematologic expertise, potentially accelerating later-stage data.
Key entities
- companyAldeyra Therapeutics, Inc.
Biotech developer of ADX‑2191.
- regulatory_bodyFDA Division of Ophthalmology
Current reviewer of the IND.
- regulatory_bodyFDA Division of Hematologic Malignancies 2
Requested new reviewer for the IND.
